{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:38:18Z","timestamp":1791509898195,"version":"4.3.4"},"reference-count":73,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Down syndrome (DS) caused by a trisomy of chromosome 21 (HSA21), is the most common genetic developmental disorder, with an incidence of 1 in 800 live births. Its phenotypic characteristics include intellectual impairment, early onset of Alzheimer\u2019s disease, congenital heart disease, hypotonia, muscle weakness and several other developmental abnormalities, for the majority of which the pathogenetic mechanisms remain unknown. Among the numerous protein coding genes of HSA21, dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A) encodes a proline-directed serine\/threonine and tyrosine kinase that plays pleiotropic roles in neurodevelopment in both physiological and pathological conditions. Numerous studies point to a crucial role of DYRK1A protein for brain defects in patients with DS. Thus, DYRK1A inhibition has shown benefits in several mouse models of DS, including improvement of cognitive behaviour. Lastly, a recent clinical trial has shown that epigallocatechine gallate (EGCG), a DYRK1A inhibitor, given to young patients with DS improved visual recognition memory, working memory performance and adaptive behaviour.<\/jats:p>","DOI":"10.3390\/brainsci8100187","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T02:52:53Z","timestamp":1539658373000},"page":"187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9445","authenticated-orcid":false,"given":"Anis","family":"Feki","sequence":"first","affiliation":[{"name":"Service de gyn\u00e9cologie obst\u00e9trique, HFR Fribourg-H\u00f4pital cantonal, Chemin des Pensionnats 2-6, Case Postale, 1708 Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Hibaoui","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine and Development, University of Geneva Medical School and Geneva University Hospitals, 1 rue Michel-Servet, 1211 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrg.2016.154","article-title":"Down syndrome and the complexity of genome dosage imbalance","volume":"18","author":"Antonarakis","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nrn3314","article-title":"Down syndrome: The brain in trisomic mode","volume":"13","author":"Dierssen","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1474-4422(16)00063-6","article-title":"Dementia in down\u2019s syndrome","volume":"15","author":"Ballard","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1742-4658.2010.07956.x","article-title":"Activation, regulation, and inhibition of dyrk1a","volume":"278","author":"Becker","year":"2011","journal-title":"FEBS J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1742-4658.2010.07954.x","article-title":"Mnb\/dyrk1a as a multiple regulator of neuronal development","volume":"278","author":"Tejedor","year":"2011","journal-title":"FEBS J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neulet.2006.11.026","article-title":"Trisomy-driven overexpression of dyrk1a kinase in the brain of subjects with down syndrome","volume":"413","author":"Dowjat","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1006\/geno.1999.5775","article-title":"Humanminibrainhomologue (mnbh\/dyrk1): Characterization, alternative splicing, differential tissue expression, and overexpression in down syndrome","volume":"57","author":"Guimera","year":"1999","journal-title":"Genomics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ajhg.2008.03.001","article-title":"Truncation of the down syndrome candidate gene dyrk1a in two unrelated patients with microcephaly","volume":"82","author":"Hoeltzenbein","year":"2008","journal-title":"Am. J. Human Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajmg.a.33735","article-title":"Clinical manifestations of the deletion of down syndrome critical region including dyrk1a and kcnj6","volume":"155","author":"Yamamoto","year":"2011","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000320113","article-title":"Distinctive phenotypic abnormalities associated with submicroscopic 21q22 deletion including dyrk1a","volume":"1","author":"Oegema","year":"2010","journal-title":"Mol. Syndromol."},{"key":"ref_11","first-page":"126","article-title":"Disruptive de novo mutations of dyrk1a lead to a syndromic form of autism and id","volume":"21","author":"Coe","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ejmg.2012.03.011","article-title":"Molecular cytogenetic characterization of an interstitial deletion of chromosome 21 (21q22.13q22.3) in a patient with dysmorphic features, intellectual disability and severe generalized epilepsy","volume":"55","author":"Valetto","year":"2012","journal-title":"Eur. J. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/jmedgenet-2012-101251","article-title":"The dyrk1a gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy","volume":"49","author":"Courcet","year":"2012","journal-title":"J. Med. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/ejhg.2015.29","article-title":"Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in dyrk1a","volume":"23","author":"Bronicki","year":"2015","journal-title":"Eur. J. Human Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/ejhg.2015.71","article-title":"Dyrk1a haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies","volume":"23","author":"Ji","year":"2015","journal-title":"Eur. J. Human Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/jmedgenet-2014-102554","article-title":"Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing","volume":"51","author":"Redin","year":"2014","journal-title":"J. Med. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Luco, S.M., Pohl, D., Sell, E., Wagner, J.D., Dyment, D.A., and Daoud, H. (2016). Case report of novel dyrk1a mutations in 2 individuals with syndromic intellectual disability and a review of the literature. BMC Med. Genet., 17.","DOI":"10.1186\/s12881-016-0276-4"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/cge.12492","article-title":"Targeted next-generation sequencing in the diagnosis of neurodevelopmental disorders","volume":"88","author":"Okamoto","year":"2015","journal-title":"Clin. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejmg.2014.12.014","article-title":"Dyrk1a mutations in two unrelated patients","volume":"58","author":"Ruaud","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2005.02.004","article-title":"Alterations in the phenotype of neocortical pyramidal cells in the dyrk1a+\/\u2212 mouse","volume":"20","author":"Dierssen","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1128\/MCB.22.18.6636-6647.2002","article-title":"Dyrk1a haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice","volume":"22","author":"Fotaki","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2012.01.007","article-title":"Dyrk1a: A master regulatory protein controlling brain growth","volume":"46","author":"Guedj","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/hmg\/10.18.1915","article-title":"Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing dyrk1a (minibrain), a murine model of down\u2019s syndrome","volume":"10","author":"Altafaj","year":"2001","journal-title":"Human Mol. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nbd.2005.12.006","article-title":"Dyrk1a bac transgenic mice show altered synaptic plasticity with learning and memory defects","volume":"22","author":"Ahn","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1242\/dmm.007716","article-title":"The use of mouse models to understand and improve cognitive deficits in down syndrome","volume":"4","author":"Das","year":"2011","journal-title":"Dis. Mod. Mech."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10519-017-9835-5","article-title":"Differential brain, cognitive and motor profiles associated with partial trisomy. Modeling down syndrome in mice","volume":"47","author":"Roubertoux","year":"2017","journal-title":"Behav. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ng0597-28","article-title":"Functional screening of 2 mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with down syndrome","volume":"16","author":"Smith","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fnbeh.2016.00104","article-title":"Dyrk1a, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome","volume":"10","author":"Duchon","year":"2016","journal-title":"Front. Behav. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1a (dyrk1a) inhibitors: A survey of recent patent literature","volume":"27","author":"Nguyen","year":"2017","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1073\/pnas.1704143114","article-title":"Prenatal neurogenesis induction therapy normalizes brain structure and function in down syndrome mice","volume":"114","author":"Awaya","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1242\/dev.066167","article-title":"Transient expression of mnb\/dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27kip1 expression and suppressing notch signaling","volume":"138","author":"Ulin","year":"2011","journal-title":"Development"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1101\/gad.2034211","article-title":"Dyrk1a protein kinase promotes quiescence and senescence through dream complex assembly","volume":"25","author":"Litovchick","year":"2011","journal-title":"Genes Develop."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31895","DOI":"10.1074\/jbc.M110.147520","article-title":"Dyrk1a phosphorylates p53 and inhibits proliferation of embryonic neuronal cells","volume":"285","author":"Park","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.4711-09.2010","article-title":"Dyrk1a overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells","volume":"30","author":"Yabut","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molcel.2013.09.009","article-title":"Dosage of dyrk1a shifts cells within a p21-cyclin d1 signaling map to control the decision to enter the cell cycle","volume":"52","author":"Chen","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0092-8674(04)00248-X","article-title":"A small modulatory dsrna specifies the fate of adult neural stem cells","volume":"116","author":"Kuwabara","year":"2004","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2005.03.013","article-title":"Rest and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis","volume":"121","author":"Ballas","year":"2005","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Abrajano, J.J., Qureshi, I.A., Gokhan, S., Zheng, D., Bergman, A., and Mehler, M.F. (2009). Rest and corest modulate neuronal subtype specification, maturation and maintenance. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007936"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0140-6736(02)07497-4","article-title":"Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with down\u2019s syndrome: A gene expression study","volume":"359","author":"Bahn","year":"2002","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/emmm.201302848","article-title":"Modelling and rescuing neurodevelopmental defect of down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21","volume":"6","author":"Hibaoui","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.15252\/embr.201540374","article-title":"Dyrk1a overexpression enhances stat activity and astrogliogenesis in a down syndrome mouse model","volume":"16","author":"Kurabayashi","year":"2015","journal-title":"EMBO Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature04678","article-title":"Nfat dysregulation by increased dosage of dscr1 and dyrk1a on chromosome 21","volume":"441","author":"Arron","year":"2006","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/glia.22797","article-title":"Nfat transcription factors regulate survival, proliferation, migration, and differentiation of neural precursor cells","volume":"63","author":"Neria","year":"2015","journal-title":"Glia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1474-4422(10)70112-5","article-title":"Cognitive deficits and associated neurological complications in individuals with down\u2019s syndrome","volume":"9","author":"Lott","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of dyrk1a in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pbb.2015.09.002","article-title":"Low dose egcg treatment beginning in adolescence does not improve cognitive impairment in a down syndrome mouse model","volume":"138","author":"Stringer","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.physbeh.2017.05.003","article-title":"Epigallocatechin-3-gallate (egcg) consumption in the ts65dn model of down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes","volume":"177","author":"Stringer","year":"2017","journal-title":"Physiol. Behav."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2012.11.017","article-title":"Normalization of dyrk1a expression by aav2\/1-shdyrk1a attenuates hippocampal-dependent defects in the ts65dn mouse model of down syndrome","volume":"52","author":"Altafaj","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neurobiolaging.2017.05.002","article-title":"Age exacerbates abnormal protein expression in a mouse model of down syndrome","volume":"57","author":"Ahmed","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/pr2011582","article-title":"Loss of correlations among proteins in brains of the ts65dn mouse model of down syndrome","volume":"11","author":"Ahmed","year":"2012","journal-title":"J. Proteome Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Cerro, S., Mart\u00ednez, P., Vidal, V., Corrales, A., Fl\u00f3rez, J., Vidal, R., Rueda, N., Arbon\u00e9s, M.L., and Mart\u00ednez-Cu\u00e9, C. (2014). Overexpression of dyrk1a is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of down syndrome. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106572"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2017.12.002","article-title":"Cerebellar alterations in a model of down syndrome: The role of the dyrk1a gene","volume":"110","author":"Vidal","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nbd.2014.04.016","article-title":"Excitation\/inhibition balance and learning are modified by dyrk1a gene dosage","volume":"69","author":"Souchet","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1601-183X.2008.00428.x","article-title":"Molecular responses of the ts65dn and ts1cje mouse models of down syndrome to mk-801","volume":"7","author":"Siddiqui","year":"2008","journal-title":"Genes Brain Behav."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/DDDT.S51476","article-title":"Pharmacological approaches to improving cognitive function in down syndrome: Current status and considerations","volume":"9","author":"Gardiner","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fnbeh.2015.00265","article-title":"Timing of therapies for down syndrome: The sooner, the better","volume":"9","author":"Stagni","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Guedj, F., S\u00e9bri\u00e9, C., Rivals, I., Ledru, A., Paly, E., Bizot, J.C., Smith, D., Rubin, E., Gillet, B., and Arbones, M. (2009). Green tea polyphenols rescue of brain defects induced by overexpression of Dyrk1a. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004606"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nbd.2013.08.008","article-title":"Environmental enrichment rescues dyrk1a activity and hippocampal adult neurogenesis in tgdyrk1a","volume":"60","author":"Dierssen","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1523\/JNEUROSCI.2852-13.2014","article-title":"Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene Dyrk1a","volume":"34","author":"Thomazeau","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fnbeh.2015.00267","article-title":"Pharmacological correction of excitation\/inhibition imbalance in down syndrome mouse models","volume":"9","author":"Souchet","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin-3-gallate, a dyrk1a inhibitor, rescues cognitive deficits in down syndrome mouse models and in humans","volume":"58","author":"Pons","year":"2014","journal-title":"Mol. Nut. Food Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ajhg.2008.09.010","article-title":"Targeting dyrk1a with aavshrna attenuates motor alterations in tgdyrk1a, a mouse model of down syndrome","volume":"83","author":"Altafaj","year":"2008","journal-title":"Am. J. Human Genet."},{"key":"ref_63","first-page":"330","article-title":"Principal component analysis of the effects of environmental enrichment and (-)-epigallocatechin-3-gallate on age-associated learning deficits in a mouse model of down syndrome","volume":"9","author":"Erb","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuroscience.2016.07.031","article-title":"Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65dn mouse model of down syndrome","volume":"333","author":"Stagni","year":"2016","journal-title":"Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s11064-007-9494-7","article-title":"Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate","volume":"33","author":"Xie","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fphys.2012.00267","article-title":"Human pluripotent stem cells: Applications and challenges in neurological diseases","volume":"3","author":"Hibaoui","year":"2012","journal-title":"Front. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/jcm4040696","article-title":"Concise review: Methods and cell types used to generate down syndrome induced pluripotent stem cells","volume":"4","author":"Hibaoui","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.gdata.2014.07.006","article-title":"Data in brief: Transcriptome analysis of induced pluripotent stem cells from monozygotic twins discordant for trisomy 21","volume":"2","author":"Hibaoui","year":"2014","journal-title":"Genom. Data"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1474-4422(16)30034-5","article-title":"Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with down\u2019s syndrome (tesdad): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Hernandez","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Noll, C., Planque, C., Ripoll, C., Guedj, F., Diez, A., Ducros, V., Belin, N., Duchon, A., Paul, J.-L., and Badel, A. (2009). Dyrk1a, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this down-syndrome-associated kinase. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007540"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrd3577","article-title":"Induced pluripotent stem cells\u2014Opportunities for disease modelling and drug discovery","volume":"10","author":"Grskovic","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of astrazeneca\u2019s drug pipeline: A five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Phase II and phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/8\/10\/187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:25:51Z","timestamp":1760196351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/8\/10\/187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":73,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["brainsci8100187"],"URL":"https:\/\/doi.org\/10.3390\/brainsci8100187","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]}}}